HOXA9 and central nervous system cancer: While drugs directly interfering with HOTAIR function are currently being studied [44–47] but still not clinically used in glioma, it may be interesting to test pharmacological approaches that act upstream of HOTAIR activation, namely PI3K inhibitors (e.g., PI-103 [48] and LY294002 [49]) that have been shown to silence HOXA9 transcription, and might thus result in HOTAIR downregulation.